PDF file       product list       search       home page       email       legal notice    

ABX  advanced biochemical compounds   


Catalogue
Number
Product Order number / Unit

9772 DOTA-TATE acetate (GMP) 9772.0000.05: 50 μg per vial
9772.0000.10: 100 μg per vial
9772.0000.25: 250 μg per vial
9772.0000.40: 400 μg per vial
9772.0001: 1 mg per vial
Please inquire for customized filling and bulk quantities.

 
Precursor for radiolabelled DOTA-[Tyr3]octreotate
Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19)
Sold under license for patent EP1872800
Molar Mass: 1435.63
C65H90N14O19S2
[177943-89-4]
Colourless to off-white solid packaged in clear glass vials with inner cone and crimp cap (9772.0000.05, 9772.0000.10, 9772.0000.25 and 9772.0000.40) or dark glass screw cap vials. (9772.0001)
Purity: > 97 % (9772.0001)
> 95 % (9772.0000.05, 9772.0000.10, 9772.0000.25 and 9772.0000.40)
Certificates:
CoA with ESI-MS (identity); HPLC (purity); GC (residual solvents, acetate content, water content); microbiology test
Chemical Name:
DOTA-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH, cyclic disulfide
DOTA = N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-
Supplied as acetate salt
Synonymes:
DOTA-[Tyr3]-Octreotate, DOTA-[Tyr3, Thr8]-Octreotide
Literature:
De Jong M. et al. Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs. J. Nucl. Med., 2005, 46,13S
Valkema R. et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3-Octreotate. J. Nucl. Med. 2005, 46, 8
date of product catalogue issue: 20 July 2015

 
 
 

  PDF file       product list       home page       search       email       legal notice